On April 11, 2023, the Board of Directors of Editas Medicine, Inc., upon recommendation of the Board's Nominating and Corporate Governance Committee, increased the size of the Board by one member and appointed Elliot Levy, M.D. as an independent director, effective immediately. Dr. Levy has been designated as a class I director to serve in accordance with the Company's By-Laws. Dr. Levy was also appointed to the Audit Committee and the Science and Technology Committee of the Board.

Dr. Levy is currently a Venture Partner at 5AM Venture Management, LLC, a venture capital firm, which he joined in April 2022. He was previously employed at Amgen, Inc., a public biopharmaceutical company, where he served as Senior Vice President of Research and Development from June 2020 to May 2021 and as Senior Vice President of Global Development from September 2014 to June 2020. He currently serves on the boards of directors of Omega Therapeutics, Inc. and NuCana plc, both public biotechnology firms, and is a co-founder and former chief executive officer of Intrepid Alliance, an industry-led non-profit consortium whose objective is to accelerate the development of small molecule therapeutics for potential viral pandemic agents.

Dr. Levy received his B.A. in History from Yale College and an M.D. from the Yale School of Medicine.